Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

BACKGROUND: Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODS: ER-positive early breast cancer patients operated at Ruijin Hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278709/
https://www.ncbi.nlm.nih.gov/pubmed/34256710
http://dx.doi.org/10.1186/s12885-021-08555-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278709/
https://www.ncbi.nlm.nih.gov/pubmed/34256710
http://dx.doi.org/10.1186/s12885-021-08555-4

Ejemplares similares